Akoya Biosciences, Inc. (NASDAQ:AKYA – Get Rating) Director Garry Ph.D. Nolan sold 22,191 shares of the firm’s stock in a transaction on Friday, September 9th. The shares were sold at an average price of $13.31, for a total value of $295,362.21. Following the completion of the transaction, the director now owns 632,893 shares in the company, valued at approximately $8,423,805.83. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Garry Ph.D. Nolan also recently made the following trade(s):
- On Monday, September 12th, Garry Ph.D. Nolan sold 1,800 shares of Akoya Biosciences stock. The stock was sold at an average price of $13.30, for a total transaction of $23,940.00.
Akoya Biosciences Stock Down 2.9 %
Shares of AKYA opened at $12.64 on Wednesday. The firm has a market cap of $475.14 million, a P/E ratio of -7.48 and a beta of 0.93. Akoya Biosciences, Inc. has a 12-month low of $8.02 and a 12-month high of $21.21. The company’s 50-day moving average price is $13.58 and its 200 day moving average price is $11.70. The company has a current ratio of 3.55, a quick ratio of 3.16 and a debt-to-equity ratio of 0.48.
Institutional Trading of Akoya Biosciences
A number of institutional investors and hedge funds have recently bought and sold shares of AKYA. Nisa Investment Advisors LLC purchased a new stake in Akoya Biosciences during the second quarter worth about $26,000. American International Group Inc. increased its stake in Akoya Biosciences by 10.8% during the second quarter. American International Group Inc. now owns 7,381 shares of the company’s stock worth $95,000 after purchasing an additional 718 shares during the period. JPMorgan Chase & Co. grew its position in shares of Akoya Biosciences by 34.0% during the second quarter. JPMorgan Chase & Co. now owns 8,431 shares of the company’s stock worth $108,000 after buying an additional 2,138 shares in the last quarter. State Board of Administration of Florida Retirement System acquired a new position in shares of Akoya Biosciences during the second quarter worth about $131,000. Finally, Rhumbline Advisers acquired a new position in shares of Akoya Biosciences during the second quarter worth about $217,000. 34.54% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
AKYA has been the topic of several recent research reports. TheStreet raised shares of Akoya Biosciences from a “d” rating to a “c-” rating in a research note on Thursday, July 21st. Piper Sandler boosted their price objective on shares of Akoya Biosciences from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, August 17th. Finally, BTIG Research boosted their price objective on shares of Akoya Biosciences to $20.00 in a report on Monday, August 15th.
Akoya Biosciences Company Profile
Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
- Get a free copy of the StockNews.com research report on Akoya Biosciences (AKYA)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle’s FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.